Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study (vol 35, pg 141, 2017)

被引：1
|
作者：
Perez
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 20期
关键词：
D O I：
10.1200/JCO.2017.74.3971
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2342 / 2342
页数：1
相关论文
共 50 条
  • [31] Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population
    Noda-Narita, Shoko
    Shimomura, Akihiko
    Kawachi, Asuka
    Sumiyoshi-Okuma, Hitomi
    Sudo, Kazuki
    Shimoi, Tatsunori
    Noguchi, Emi
    Yonemori, Kan
    Shimizu, Chikako
    Fujiwara, Yasuhiro
    Tamura, Kenji
    BREAST CANCER, 2019, 26 (04) : 492 - 498
  • [32] Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population
    Shoko Noda-Narita
    Akihiko Shimomura
    Asuka Kawachi
    Hitomi Sumiyoshi-Okuma
    Kazuki Sudo
    Tatsunori Shimoi
    Emi Noguchi
    Kan Yonemori
    Chikako Shimizu
    Yasuhiro Fujiwara
    Kenji Tamura
    Breast Cancer, 2019, 26 : 492 - 498
  • [33] Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2-Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial
    Yamashita, Toshinari
    Saji, Shigehira
    Takano, Toshimi
    Naito, Yoichi
    Tsuneizumi, Michiko
    Yoshimura, Akiyo
    Takahashi, Masato
    Tsurutani, Junji
    Iwatani, Tsuguo
    Kitada, Masahiro
    Tada, Hiroshi
    Mori, Natsuko
    Higuchi, Toru
    Iwasa, Tsutomu
    Araki, Kazuhiro
    Koizumi, Kei
    Hasegawa, Hiroki
    Uchida, Yohei
    Morita, Satoshi
    Masuda, Norikazu
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (11)
  • [34] Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with trastuzumab-insensitive human epidermal growth factor receptor 2-positive metastatic breast cancer
    Portera, Chia C.
    Walshe, Janice M.
    Rosing, Douglas R.
    Denduluri, Neelima
    Berman, Arlene W.
    Vatas, Ujala
    Velarde, Margarita
    Chow, Catherine K.
    Steinberg, Seth M.
    Nguyen, Diana
    Yang, Sherry X.
    Swain, Sandra M.
    CLINICAL CANCER RESEARCH, 2008, 14 (09) : 2710 - 2716
  • [35] Phase III Randomized Study Comparing Docetaxel Plus Trastuzumab With Vinorelbine Plus Trastuzumab As First-Line Therapy of Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The HERNATA Study
    Andersson, Michael
    Lidbrink, Elisabeth
    Bjerre, Karsten
    Wist, Erik
    Enevoldsen, Kristin
    Jensen, Anders B.
    Karlsson, Per
    Tange, Ulla B.
    Sorensen, Peter G.
    Moller, Susanne
    Bergh, Jonas
    Langkjer, Sven T.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (03) : 264 - 271
  • [36] Patient-reported outcomes (PROs) from MARIANNE: A phase III study of trastuzumab emtansine (T-DM1) +/- pertuzumab (P) vs trastuzumab plus taxane (HT) for HER2-positive advanced breast cancer.
    Barrios, Carlos H.
    Cella, David
    Martin, Miguel
    Eiermann, Wolfgang
    Burris, Howard A.
    Im, Young-Hyuck
    Conte, Pier Franco
    Toi, Masakazu
    Pienkowski, Tadeusz
    Pivot, Xavier B.
    Beckermann, Benjamin
    Stanzel, Sven Franz
    Petersen, Jennifer
    Ellis, Paul Anthony
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [37] A phase II study of eribulin mesylate in combination with trastuzumab and pertuzumab in patients (pts) with metastatic, human epidermal growth factor receptor 2-positive breast cancer
    Freedman, Rachel A.
    Luis, Ines Maria Vaz Duarte
    Barry, William Thomas
    Krop, Ian E.
    Wagle, Nikhil
    Lowe, Alarice
    Galler, Sarah
    Sohl, Jessica
    Isakoff, Steven J.
    Tung, Nadine M.
    Winer, Eric P.
    Lin, Nancy U.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [38] Phase III study of trastuzumab deruxtecan (T-DXd) with or without pertuzumab vs a taxane, trastuzumab and pertuzumab in first-line (1L), human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (mBC): DESTINY-Breast09
    Tolaney, S. M.
    Barroso-Sousa, R.
    Jiang, Z.
    Park, Y. H.
    Rimawi, M.
    Manich, C. Saura
    Schneeweiss, A.
    Toi, M.
    Yu, T.
    Shetty, J.
    Herbolsheimer, P.
    Loibl, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S507 - S508
  • [39] Substituting adjuvant trastuzumab emtansine for Herceptin improves survival in patients with human epidermal growth factor receptor 2-positive breast cancer
    Printz, Carrie
    CANCER, 2019, 125 (08) : 1213 - 1213
  • [40] Phase II study of eribulin in combination with pertuzumab plus trastuzumab for human epidermal growth factor receptor 2 (HER2)-positive advanced or metastatic breast cancer
    Kawaguchi, Hidetoshi
    Yamashita, Toshinari
    Masuda, Norikazu
    Kitada, Masahiro
    Narui, Kazutaka
    Hattori, Masaya
    Yoshinami, Tetsuhiro
    Matsunami, Nobuki
    Yanagihara, Kazuhiro
    Kawasoe, Teru
    Nagashima, Takeshi
    Bando, Hiroko
    Yano, Hiroshi
    Hasegawa, Yoshie
    Nakamura, Rikiya
    Kashiwaba, Masahiro
    Morita, Satoshi
    Ohno, Shinji
    Toi, Masakazu
    CANCER RESEARCH, 2018, 78 (04)
12345